Three-step radioimmunotherapy with yttrium-90 biotin: Dosimetry and pharmacokinetics in cancer patients

European Journal of Nuclear Medicine

Volumn 26, Issue 2, 1999, Pages 110-120

  Cremonesi, Marta ^a   Ferrari, Mahila ^a   Chinol, Marco ^a   Stabin, Michael G ^b   Grana, Chiara ^a   Prisco, Gennaro ^a   Robertson, Chris ^a   Tosi, Giampiero ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

Author keywords

Biotin; Dosimetry; Pretargeting; Radioimmunotherapy; Yttrium 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AVIDIN; BIOTIN; CHELATING AGENT; INDIUM 111; MONOCLONAL ANTIBODY; PENTETIC ACID; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; BLADDER; BLOOD TOXICITY; BONE MARROW; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TARGETING; HUMAN; KIDNEY; LIVER; PHOTON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; URINARY EXCRETION;

ANTIBODIES, MONOCLONAL; AVIDIN; BIOTINYLATION; BONE MARROW; CHELATING AGENTS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KIDNEY; LIVER; MODELS, BIOLOGICAL; NEOPLASMS; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; STREPTAVIDIN; TOMOGRAPHY, EMISSION-COMPUTED; URINARY BLADDER; WHOLE-BODY COUNTING; YTTRIUM RADIOISOTOPES;

EID: 0033054395     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050366     Document Type: Article

References (48)

1. Bischof Delaloye A, Delaloye B. Radiolabelled monoclonal antibodies in tumor imaging and therapy: out of fashion? Eur J Nucl Med 1995; 22: 571-580.
2. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med 1995; 36: 876-879.
3. 90Y-biotin in glioma patients. Eur J Nucl Med 1997; 24: 908.
4. Wessels BW, Buchsbaum DJ. Dosimetry of radiolabeled antibodies. In: Smith AR, ed. Radiation therapy physics. Berlin Heidelberg New York: Springer; 1995: 365-384.
5. Siegel JA, Pawlyk DA, Lee RE, et al. Tumor, red marrow and organ dosimetry for I131-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50(Suppl): 1039-1042.
6. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 1993; 34: 908-917.
7. Borchardt PE, Quadri SM, Freedman RS, et al. Indium-111-and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice. J Nucl Med 1998; 39: 476-484.
8. Breitz H, Ratliff B, Reno J, Axworthy D, Fritzberg A, Su FM, Appelbaum J, Kunz S, Seileer C, Weiden P. Performance of antibody streptavidin pretargeting in patients: initial results. J Nucl Med 1995; 36: 225P.
9. Su F-M, Hickey JJ, Taylor C, Beaumier P. In-111/Y-90 dual isotope scintillation counting method for patient samples from pretargeted cancer therapy phase I trial. J Nucl Med 1996; 37: 144P.
10. Colcher D, Esteban J, Carasquillo JA. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987; 47: 4218-4224.
11. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960-5966.
12. Su FM, Gustavson LM, Axworthy DB, et al. Characterization of a new Y-90 labeled DOTA-biotin for pretargeting. J Nucl Med 1995; 36: 154P.
13. Paganelli G, Magnani P, Chinol M, et al. Pilot therapy trial of CEA positive tumours using a three-step pretargeting approach. Tumor Targeting 1998; 3: 69-104.
14. Thomas SR, Maxon RH, Kereiakes JG. Techniques for quantitation of in-vivo radioactivity. In: Gelfand MJ, Thomas SR, eds. Effective use of computers in nuclear medicine. New York: McGraw-Hill; 1988: 468-484.
15. Ott RJ. Imaging technologies for radionuclide dosimetry. Phys Med Biol 1996; 41: 1885-1894.
16. Van Rensburg AJ, Lotter MG, Heyns AP, et al. An evaluation of four methods of 111-In planar image quantification. Med Phys 1988; 15: 853-861.
17. Coffey YL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys 1979; 6: 307-308.
18. Foster D, Barret P. Developing and testing integrated multi-compartment models to describe a single-input multiple-output study using the SAAM II software system. Proc. Sixth International Radiopharmaceutical. Dosimetry Symposium, Oak Ridge Institute for Science and Education, 1998.
19. Robertson J. Compartmental distribution of radiotracer. New York: CRC Press; 1983: 73-142.
20. Stabin MG, Kooij PPM, Bakker WH, et al. Radiation dosimetry for indium-111-pentreotide. J Nucl Med 1997; 38: 1919-1922.
21. Cloutier R, Smith S, Watson E, Snyder W, Warner G. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25: 147-161.
22. Thomas SR, Stabin MG, Chin-Tu C, et al. MIRD Pamphlet n. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med 1992; 33: 783-802.
23. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
24. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 689-694.
25. Trunnell JB, Duffy JB, Goodwin JT, et al. The distributions of radioactive iodine in human tissues: necropsy study in 9 patients. J Clin Endocrinol 1950; 10: 1007-1021.
26. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunocojugates Radiopharm 1990; vol. 3, no. 4.
27. Goddu SM, Howell RW, Giuliani DC, Dandamudi VR. Biological dosimetry of bone marrow for incorporated yttrium-90. J Nucl Med 1998; 39: 547-552.
28. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994; 35: 152-156.
29. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 1490-1497.
30. Moi MK, Meares CF. The peptide way to macrocyclic bifunctional chelating agents: syntesis of 2-(p-nitroben-zyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetra-acetic acid and study of its yttrium(III) complex. J Am Chem Soc 1988; 110: 6266-6267.
31. Deshpande SV, De Nardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990; 31: 473-479.
32. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30. New York: Pergamon Press, 1979.
33. Loevinger R, Budinger T, Watson E. MIRD Primer for absorbed dose calculation. Reston, VA: Society of Nuclear Medicine; 1988: 1-10.
34. A practical guide to EORTC studies. Brussels: EORCT, 1994.
35. Efrom B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman & Hall, 1993.
36. International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection. ICRP Publication 60. New York: Pergamon Press; 1991: 68.
37. Poston M. Application of the effective dose equivalent to nuclear medicine patients. J Nucl Med 1993; 34: 714-716.
38. Stabin MG, Stubbs J, Watson E. Recent controversy in radiation dosimetry. Eur J Nucl Med 1993; 20: 371-372.
39. Paganelli G, Chinol M, Maggiolo M, Sidoli A, Corti A, Baroni S, Siccardi A. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmuscintigraphy and radioimmunotherapy. Eur J Nucl Med 1997; 24: 350-351
40. Fazio F, Paganelli G. Antibody-guided scintigraphy: targeting of the magic bullet. Eur J Nucl Med 1993; 20: 1138-1140.
41. Magnani P, Paganelli G, Modorati G, et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996; 37: 967-971.
42. De Nardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy of breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997; 38: 1180-1185.
43. De Nardo SJ, Richman CM, Goldenstein DS, et al. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997; 17(3B): 1735-1744.
44. Jowsey J, Rowland RE, Marshall JH, et al. The deposition of the rare earths in bone. Radiat Res 1958; 8: 490-501.
45. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in-vivo survival and toxicity. Cancer Res 1989; 49: 2639-2644.
46. Sundberg MW, Meares CF, Goodwin DA, et al. Chelating agents for the binding of metal ions to macromolecules. Nature 1974; 250: 587-588.
47. 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 1991; 18: 469-476.
48. 90Y-labelled biotins using three-step tumour targeting. Nucl Med Commun 1997; 18: 176-182